WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company’s product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.

新泽西州沃伦（WARREN，N.J.），2024年4月12日（GLOBE NEWSWIRE）--Aquestive Therapeutics，Inc.（纳斯达克：AQST）（“公司”或“Aquestive”）是一家制药公司，通过创新的科学和交付技术推动药物的发展，为患者的生活带来有意义的改善。今天，该公司宣布了一份海报展示，重点介绍了该公司产品候选产品Libervant™（地西泮）颊膜治疗2至5岁癫痫儿童的交叉研究，将于4月13日至18日在丹佛举行的美国神经病学学会（AAN）第76届年会上展出，以混合形式提供亲自出席和在线直播参与。

“This study underscores our ongoing dedication to enhancing the well-being of individuals battling epilepsy,” said Dan Barber, Aquestive President and Chief Executive Officer. “When it comes to the treatment of seizure clusters in pediatric patients with epilepsy between ages two to five, we believe Libervant, as an oral alternative to existing device-based products, will be well-received by this patient population.” Poster Title: Crossover Study Evaluating the Effect of Seizures on the Absorption of Diazepam From a Buccal Film Formulation in Children With EpilepsyPoster Session 9: Epilepsy/Clinical Neurophysiology (EEG): Anti-seizure Medications: Mechanisms, Pharmacokinetics, and Urgent ApplicationsPresentation Time: Wednesday, April 17, from 8:00 AM - 9:00 AM.Lead Author: Gary Slatko, MD, Steve Wargacki, PhD, Michael A.

Aquestive总裁兼首席执行官丹·巴伯（DanBarber）表示：“这项研究突显了我们正在致力于提高癫痫患者的幸福感。”。“当涉及到治疗2至5岁儿童癫痫患者的癫痫发作集群时，我们相信Libervant作为现有基于设备的产品的口服替代品，将受到该患者群体的欢迎。”海报标题：交叉研究评估癫痫发作对癫痫儿童口腔膜制剂中地西泮吸收的影响海报第9期：癫痫/临床神经生理学（EEG）：抗癫痫药物：机制，药代动力学和紧急应用介绍时间：4月17日星期三上午8:00至9:00。主要作者：Gary Slatko，MD，Steve Wargacki，PhD，Michael a。

Rogawski, MD, PhD The abstract is available online at American Academy of Neurology Annual Meeting, as well on the Company’s website at the following Link. About Libervant Libervant is a buccally, or inside of the cheek, administered film formulation of diazepam, a benzodiazepine inte.

Rogawski，医学博士，博士摘要可在美国神经病学学会年会上在线获得，也可在公司网站上的以下链接获得。关于Libervant Libervant是地西泮（一种苯二氮卓类药物）的口腔或脸颊内给药薄膜制剂。